Results 251 to 260 of about 6,399,825 (302)
Some of the next articles are maybe not open access.

Genetically Modified Tumor Cell Vaccines

Surgical Oncology Clinics of North America, 1998
Recent progress in identifying tumor antigens and understanding the host-tumor relationship have catalyzed a dramatic expansion of efforts to develop cancer vaccines. Gene transfer technologies have figured prominently in the design of many of these novel immunization schemes.
F S, Hodi, G, Dranoff
openaire   +2 more sources

Tumor vaccines in renal cell carcinoma

World Journal of Urology, 2008
Although most vaccines target foreign infectious agents, therapeutic cancer vaccines target both well-established and metastatic tumor cells expressing tumor antigens. Active immunotherapy is intended to enhance or activate the immunosurveillance of an individual through a therapeutic vaccine.
Hirotsugu, Uemura, Marco A, De Velasco
openaire   +2 more sources

Overview of Tumor Cell–Based Vaccines

International Reviews of Immunology, 2006
Whole-cell tumor vaccines have been investigated for more than 20 years for their efficacy in both preclinical models and in clinical trials in humans. There are clear advantages of whole-cell/polyepitope vaccination over those types of immunotherapy that target specific epitopes.
John, Copier, Angus, Dalgleish
openaire   +2 more sources

An epigenetically altered tumor cell vaccine

Cancer Immunology, Immunotherapy, 2004
Functional inactivation of genes critical to immunity may occur by mutation and/or by repression, the latter being potentially reversible with agents that modify chromatin. This study was constructed to determine whether reversal of gene silencing, by altering the acetylation status of chromatin, might lead to an effective tumor vaccine.
A Nazmul H, Khan   +2 more
openaire   +2 more sources

Processing of Tumor Tissues for Vaccination with Autologous Tumor Cells

European Surgical Research, 2008
Vaccination with gene-transfected tumor cells has recently been proposed as a new strategy in the immunotherapy of cancer. Since autologous tumor cells provide an optimal antigen profile, the possibility of generating single cell suspensions from renal cell carcinoma (RCC), malignant melanoma (MM), colon carcinoma (CC), and non-small-cell lung cancer ...
Lahn, Michael   +16 more
openaire   +3 more sources

Exosomes from Plasmacytoma Cells as a Tumor Vaccine

Journal of Immunotherapy, 2004
Exosomes are membrane-bound vesicles derived from multivesicular bodies that are externalized by cells through fusion with the plasma membrane. Exosomes have been implicated in cell-to-cell signaling, and those derived from immunologic cells may be involved in both direct and cross-presentation of antigens to T cells.
Stephen L, Altieri   +2 more
openaire   +2 more sources

Whole-Tumor-Cell Vaccines

2004
Although identification of tumor antigens has propelled the development of many different approaches to cancer immunotherapy, whole-tumor vaccines continue to be of interest because they contain a large number of antigens, known and unknown, allowing for both widely applicable as well as patient-specific vaccines. Although the presence of a progressing
Timothy M. Clay   +3 more
openaire   +1 more source

Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

Nature Medicine, 2000
The breaking of immune tolerance against autologous angiogenic endothelial cells should be a useful approach for cancer therapy. Here we show that immunotherapy of tumors using fixed xenogeneic whole endothelial cells as a vaccine was effective in affording protection from tumor growth, inducing regression of established tumors and prolonging survival ...
Y Q, Wei   +25 more
openaire   +2 more sources

Immunotherapy for Malignant Melanoma with a Tumor Cell Vaccine

Annals of Plastic Surgery, 1992
Specific active immunotherapy for melanoma has been administered to several thousand patients since 1972, using an irradiated whole-cell preparation. A humoral response to vaccination can be demonstrated in a large percentage of patients. This response increases while immunizations are continued and decreases after cessation of therapy.
C L, Slingluff, H F, Seigler
openaire   +2 more sources

Dendritic Cell-Tumor Cell Fusion Vaccines

2011
The use of cell fusion has been applied to the development of immunotherapy cancer vaccines. This has typically involved the fusion of dendritic cells and tumor cells. The resultant hybrid uses the specialized antigen presentation properties supplied by the dendritic cell fusion partner to present tumor antigens, both known and yet undefined, to the ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy